CLAIMS

1. A composition comprising T_3, serum albumin and water wherein the stability of T_3 is increased.

2. The composition according to claim 1, wherein the T_3 has a half-life of at least five days at a temperature range of about –30°C to 70°C.

3. The composition according to claim 1, wherein further comprising a pharmaceutically acceptable excipient.

4. The composition according to claim 3, suitable for use in intravenous administration.

5. The composition according to claim 3, suitable for use in direct cardiac administration.

6. The composition according to claim 3, suitable for use in parenteral administration.

7. The composition according to claim 3, suitable for use in mucosal administration.

8. The composition according to claim 7, wherein the mucosal administration is selected from the group consisting of intranasal, by-inhalation and buccal.

9. The composition according to claim 8, wherein the T_3 has a half-life of at least two weeks.

10. The composition according to claim 1, wherein the T_3 has a half-life of at least one month.

11. The composition according to claim 1, wherein the T_3 has a half-life of at least three months.

12. The composition according to claim 1, wherein the T_3 has a half-life of at least six months.

13. The composition according to claim 1, wherein the T_3 has a half-life of at least twelve months.

14. The composition according to claim 1, wherein the ratio of T_3 and the serum albumin is between about 0.001 and 0.1.

15. The composition according to claim 1, wherein the ratio of T_3 and the serum albumin is between 0.002 and 0.05.

16. The composition according to claim 3, wherein the serum albumin is human serum albumin.

17. The composition according to claim 3, wherein the serum albumin is bovine serum albumin.

18. The composition according to claim 1, wherein the T_3 has a concentration of between 0.02 mg/ml and 0.8 mg/ml.

19. The composition according to claim 1, wherein the T_3 has a concentration of between 0.01 mg/ml and 1.0 mg/ml.

20. The composition according to claim 1, wherein the T_3 has a concentration of between 0.1 mg/ml and 0.5 mg/ml.

21. The composition according to claim 1, wherein the T_3 has a concentration of about 0.1 mg/ml.

22. The composition according to claim 1, wherein the pH range is about 2.5 to 11.5.

23. The composition according to claim 1, wherein the pH range is about 4.0 to 10.

24. The composition according to claim 1, wherein the pH range is about 6.0 to 8.0.

25. The composition according to claim 1, wherein the pH range is about 6.5 to 7.5.

26. A method of treating of a patient with cardiac arrest, or with cardiac electrical standstill, to restore effective cardiac function, comprising administering to the patient a therapeutically effective amount of the composition according to claim 1.

27. The method according to claim 26, wherein the cardiac arrest is caused by electromechanical dissociation.

28. The method according to claim 26, wherein the cardiac electrical standstill is caused by a disease.

29. The method according to claim 26, wherein the composition is administered by direct injection to a heart cavity of the patient, or direct parenteral injection into a central venous line of the patient.

30. The method according to claim 26, wherein the composition is administered by parenteral injection or parenteral intravenous injection.

31. The method according to claim 26, wherein the composition is administered directly to the pulmonary system of the patient.

32. The method according to claim 26, wherein the composition is administered directly to the pulmonary system by direct endotracheal injection.

33. The method according to claim 26, wherein the composition is administered directly to the pulmonary system by infusion through a respiratory airway of the patient.

34. The method according to claim 26, wherein the composition is administered in at least one rapid bolus injection.

35. The method according to claim 26, wherein the composition is administered at between 0.1 and 20 μg T_3 per kg of body weight.

36. The method according to claim 26, wherein the composition is administered at between 0.2 and 10 μg T_3 per kg of body weight.

37. The method according to claim 26, wherein the composition is administered at between 0.3 and 5 μg T_3 per kg of body weight.

38. The method according to claim 26, wherein the composition is administered at 100 μg T_3 per kg of body weight.

39. The method according to claim 26, wherein the composition is administered via intravenous drip.

40. The method according to claim 26, wherein the composition is administered via mucosal delivery.